Document Detail


Reversal of fundic atrophy after eradication of Helicobacter pylori.
MedLine Citation:
PMID:  9732919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: We sought to evaluate the effect of Helicobacter pylori eradication in patients with fundic atrophic gastritis. METHODS: Acid secretion, gastric emptying, and histology were evaluated in 20 patients with fundic atrophic gastritis and H. pylori infection. After investigation, 10 patients (Group 1) received an eradicating treatment and 10 (Group 2) did not receive any treatment. One year later, the baseline investigations were repeated. Subsequently, patients in Group 2 received the same treatment given to patients in Group 1 and were reevaluated 12 months later. A further follow-up was performed in both groups 36 months after the treatment. RESULTS: At 1-yr follow-up, all the patients in Group 1 were H. pylori negative whereas all the patients in Group 2 were still infected. In Group 1, there was a significant improvement of both fundic atrophy and acid secretion, compared with baseline (p < 0.01). In Group 2, no substantial modification of either histological or functional parameters was observed at the first follow-up; conversely, a significant (p < 0.01) improvement of fundic atrophy and acid secretion was detected in these patients 12 months after eradication of the bacterium. Histological pattern remained unchanged at 36 months of follow-up in both groups. Gastric emptying remained, on the average, unaffected by the treatment; however, three patients with delayed gastric emptying at entry had normal gastric emptying after eradication of H. pylori. CONCLUSIONS: Our data suggest that mucosal atrophy can be reduced or even reversed by the eradication of H. pylori, and this is associated with a recovery of gastric function.
Authors:
A Tucci; L Poli; C Tosetti; G Biasco; W Grigioni; O Varoli; C Mazzoni; G F Paparo; V Stanghellini; G Caletti
Related Documents :
25356809 - Surgical interventions and medical treatments in treatment-naïve patients with acromega...
25381429 - Rituximab versus cyclophosphamide for anca-associated vasculitis with renal involvement.
14571829 - One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on...
8470629 - Patient factors affecting helicobacter pylori eradication with triple therapy.
21941449 - Benefit of intravenous antibiotic therapy in patients referred for treatment of neurolo...
1227279 - Evaluation of total ige in diverse allergosis. comparative study with other techniques....
25370599 - Worsening of renal function during 1 year after hospital discharge is a strong and inde...
19775309 - Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes ...
19812449 - Efficacy and safety of darunavir/ritonavir in treatment-experienced hiv type-1 patients...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  93     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-09-15     Completed Date:  1998-09-15     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1425-31     Citation Subset:  IM    
Affiliation:
Institute of Medical Clinic & Gastroenterology, Department of Pathology, Hospital S. Orsola-Malpighi, University of Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amoxicillin / therapeutic use
Anti-Bacterial Agents / therapeutic use
Anti-Ulcer Agents / therapeutic use
Atrophy / drug therapy,  pathology
Female
Follow-Up Studies
Gastric Acid / secretion
Gastric Emptying
Gastric Fundus / pathology
Gastritis / drug therapy,  pathology*,  physiopathology*
Helicobacter Infections / drug therapy*,  pathology,  physiopathology
Helicobacter pylori*
Humans
Male
Metronidazole / therapeutic use
Middle Aged
Organometallic Compounds / therapeutic use
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Anti-Ulcer Agents; 0/Organometallic Compounds; 26787-78-0/Amoxicillin; 443-48-1/Metronidazole; 57644-54-9/bismuth tripotassium dicitrate
Comments/Corrections
Comment In:
Am J Gastroenterol. 1998 Sep;93(9):1407-8   [PMID:  9732916 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nonsteroidal antiinflammatory drug use and gallstone disease prevalence: a case-control study.
Next Document:  Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States.